BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
Corporate history
The firm was established in 2003 as a joint venture of Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors.[2] It executed an initial public offering on the Tel Aviv Stock Exchange in February 2007, raising 211 million NIS ($50 million) – the TASE's largest biotech IPO until that time.[3][4] In July 2011 BioLine's ADRs began trading on the NASDAQ Capital Market.[5][6]